Hematopoiesis News Volume 12.45 | Nov 16 2021

    By
    Justin.choi
    -
    0
    21







    2021-11-16 | HN 12.45


    Hematopoiesis News by STEMCELL Technologies
    Vol. 12.45 – 16 November, 2021
    TOP STORY

    A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms

    Researchers presented a humanized animal model of myelofibrosis patient-derived xenografts which were robustly engrafted patient cells that recapitulated the patient’s genetic hierarchy and pathologies such as reticulin fibrosis and propagation of myeloproliferative neoplasms-initiating stem cells.
    [Cancer Discovery]

    Abstract
    Request your free copy of the 'Bone Marrow Niches and HSC Fates' Wallchart
    PUBLICATIONSRanked by the impact factor of the journal

    A Novel Role for Endoplasmic Reticulum Protein 46 (ERp46) in Platelet Function and Arterial Thrombosis in Mice

    Scientists found that ERp46 was critical for platelet function and thrombosis and facilitated αIIbβ3 activation by targeting disulfide bonds.
    [Blood]

    Abstract

    Cell Size Is a Determinant of Stem Cell Potential during Aging

    The authors found that HSCs were enlarged under conditions known to decrease stem cell function, and concluded that small cell size was important for stem cell function in vivo and proposed that stem cell enlargement contributed to their functional decline during aging.
    [Science Advances]

    Full Article

    Acute Myeloid Leukemia Maturation Lineage Influences Residual Disease and Relapse Following Differentiation Therapy

    Researchers indicated that relapse can originate from therapy-resistant mature acute myeloid leukemia cells, and suggested differentiation therapy combined with targeted eradication of mature leukemia-derived lineages may improve disease outcome.
    [Nature Communications]

    Full Article

    Nucleolar and Spindle Associated Protein 1 Enhances Chemoresistance through DNA Damage Repair Pathway in Chronic Lymphocytic Leukemia by Binding with RAD51

    Scientists investigated the mechanism by which nucleolar and spindle-associated protein 1 enhanced chemoresistance via DNA damage repair signaling by stabilizing RAD51 in chronic lymphocytic leukemia cells.
    [Cell Death & Disease]

    Full Article

    MicroRNA-155-5p Initiates Childhood Acute Lymphoblastic Leukemia by Regulating the IRF4/CDK6/CBL Axis

    The authors explored putative mechanisms of microRNA-155-5p involvement in childhood acute lymphoblastic leukemia via interactions with casitas B-lineage lymphoma (CBL), interferon regulatory factor 4 (IRF4), and cyclin-dependent kinase 6 (CDK6).
    [Laboratory Investigation]

    Abstract

    Arsenite Exposure Inhibits the Erythroid Differentiation of Human Hematopoietic Progenitor CD34+ Cells and Causes Decreased Levels of Hemoglobin

    Investigators reported that low-dose arsenic exposure inhibited the erythroid differentiation of human hematopoietic progenitor cells (HPCs).
    [Scientific Reports]

    Full Article

    Targeting CD38 in Acute Myeloid Leukemia Interferes with Leukemia Trafficking and Induces Phagocytosis

    In line with a predominantly microenvironment-mediated activity of daratumumab in acute myeloid leukemia (AML), CD38 inhibition significantly induced antibody-dependent phagocytosis and showed interference with AML cell trafficking in vivo in a xenograft transplantation model, but overall lacked robust anti-leukemic effects.
    [Scientific Reports]

    Full Article

    Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable with Isolated Isochromosome 17q Represents a Distinct Clinico-Biologic Subset: A Multi-Institutional Collaborative Study from the Bone Marrow Pathology Group

    Classification of myeloid neoplasms with isolated isochromosome i(17q) is controversial. Most cases fall within the WHO unclassifiable myelodysplastic/myeloproliferative neoplasms (MDS/MPN-U) category. Researchers undertook a multi-institutional retrospective study of 92 adult MDS/MPN-U cases.
    [Modern Pathology]

    Abstract

    Feasibility and Efficacy of Salvage Allogeneic Stem Cell Transplantation in AML Patients Relapsing after Autologous Stem Cell Transplantation

    Investigators suggested that almost 80% of acute myeloid leukemia patients could undergo salvage therapy following relapse after front-line high-dose chemotherapy/autologous hematopoietic cell transplantation.
    [Bone Marrow Transplantation]

    Full Article

    Acute Lymphoblastic Leukemia in Children and SALL4 and BMI-1 Gene Expression

    The authors evaluated the prognostic value of Sal-like protein 4 transcription factor (SALL4) and B cell-specific Moloney murine leukemia virus integration site 1 (BMI-1) in children with acute lymphoblastic leukemia.
    [Pediatric Research]

    Abstract
    Return to your lab safely and efficiently with these guides and resources so that you can focus more on moving your research goals forward.
    REVIEWS

    Clonal Hematopoiesis: From Mechanisms to Clinical Intervention

    Scientists discuss the state of clonal hematopoiesis research and outline the challenges in developing clinical trials of early interventions.
    [Cancer Discovery]

    Abstract

    Signal-Transducing Adaptor Protein-1 and -2 in Hematopoiesis and Diseases

    Recent findings have shown the critical roles of signal-transducing adaptor protein (STAP)-2 in B cell progenitor cells in marrow under hematopoietic stress and STAP-1 and -2 in BCR-ABL-transduced leukemogenesis. In this review, the authors focus on the role of STAPs in the bone marrow.
    [Experimental Hematology]

    Abstract
    INDUSTRY AND POLICY NEWS

    Biosight Announces Initiation of Phase II Clinical Trial of Aspacytarabine for MDS and AML

    Biosight Ltd.,announced the initiation of a Phase II trial to evaluate aspacytarabine, Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML).
    [Biosight Ltd. (GlobeNewswire, Inc.)]

    Press Release

    US FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera

    PharmaEssentia Corporation announced that the US FDA has approved BESREMi® for the treatment of adults with polycythemia vera. BESREMi is an innovative monopegylated, long-acting interferon, which exhibits its cellular effects in polycythemia vera in the bone marrow.
    [PharmaEssentia Corporation]

    Press Release
    FEATURED EVENT

    ASH Annual Meeting 2021

    December 11 – 14, 2021
    Atlanta, Georgia, United States

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Researcher – Translational Research

    Karolinska Institutet – Flemingsberg, Sweden

    Research Fellow – Hematologic Malignancies

    Dana-Farber Cancer Institute – Boston, Massachusetts, United States

    Postdoctoral Position – Drug Resistance

    University Children’s Hospital Zurich – Zurich, Switzerland

    Postdoctoral Position – Gene Editing

    Icahn School of Medicine at Mount Sinai – New York, New York, United States

    Postdoctoral Fellow – Functional Genomics of Hematopoiesis

    Boston Children’s Hospital – Boston, Massachusetts, United States

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Hematopoiesis News Twitter